Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO /FiO

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory research 2021-12, Vol.22 (1), p.317-317, Article 317
Hauptverfasser:	Karampitsakos, Theodoros, Malakounidou, Elli, Papaioannou, Ourania, Dimakopoulou, Vasilina, Zarkadi, Eirini, Katsaras, Matthaios, Tsiri, Panagiota, Tsirikos, Georgios, Georgiopoulou, Vasiliki, Oikonomou, Ioanna, Davoulos, Christos, Velissaris, Dimitrios, Sampsonas, Fotios, Marangos, Markos, Akinosoglou, Karolina, Tzouvelekis, Argyris
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Aged Antibodies, Monoclonal, Humanized - administration & dosage Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - drug therapy COVID-19 - mortality Departments Drug dosages Female Hospitalization Hospitalization - trends Humans Hypoxia Illnesses Inflammation Male Middle Aged Monoclonal antibodies Mortality Outcomes Oxygen therapy PaO2/FiO2 Patient Acuity Patients Prospective Studies Severe acute respiratory syndrome coronavirus 2 Statistical analysis Survival Survival Rate - trends Tocilizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO /FiO
ISSN:	1465-993X 1465-9921 1465-993X 1465-9921
DOI:	10.1186/s12931-021-01914-6